Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease Post author: Post published:April 25, 2024 Post category:uncategorized Funding represents the first time the foundation has taken an equity position in a breath diagnostics company. You Might Also Like Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17 November 12, 2024 Future Labs Live Basel 2024: Digital, Automated, Connected June 19, 2024 Sweetener saccharin revives old antibiotics by breaking bacterial defences April 3, 2025
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17 November 12, 2024